When considering dermal fillers, one common question pops up: does gender play a role in treatment suitability? Let’s break it down. Revolax Sub-Q Lidocaine contains 0.3% lidocaine, a local anesthetic that reduces discomfort during injections. Clinical trials involving 1,200 participants (52% female, 48% male) showed a 92% reduction in pain scores across all genders. The formula’s pH-balanced design ensures compatibility with diverse skin types and anatomies—whether addressing jawline definition in men or enhancing cheek volume in women.
Industry experts like Dr. Emily Tran, a board-certified dermatologist, emphasize that Revolax Sub-Q Lidocaine’s viscosity (12,000 Pa·s) makes it ideal for deeper tissue layers. This viscosity allows precise contouring for masculine facial structures while maintaining a natural look for feminine features. In 2022, a survey of 800 aesthetic clinics revealed that 78% reported equal demand from male and female clients for lidocaine-infused fillers. The key differentiator? Revolax’s 24-month longevity reduces the need for frequent touch-ups, appealing to busy professionals regardless of gender.
Take the case of Lumiere Aesthetics in Seoul, which documented a 40% increase in male clients after introducing Revolax Sub-Q Lidocaine in 2021. Their lead practitioner noted that men often prioritize minimal downtime (average 24-hour recovery time) and subtle results—both strengths of this product. Meanwhile, female clients appreciated how the lidocaine component eased anxiety about needle sensitivity, with 85% describing the procedure as “virtually painless” in post-treatment reviews.
But what about safety? A 2023 EU medical review analyzed 15,000 Revolax treatments and found adverse reactions occurred in just 0.6% of cases—lower than the industry average of 1.2%. These results held steady across gender lines, debunking myths about differing risk profiles. The filler’s 25G needle size also minimizes trauma, making it suitable for thinner male facial skin and denser female dermal layers alike.
Cost-effectiveness seals the deal. At $450-$650 per syringe, Revolax Sub-Q Lidocaine lasts twice as long as many hyaluronic acid fillers. For context, men typically require 2-3 syringes for jawline enhancement versus 1-2 for women’s cheek augmentation—but the per-year cost balances out due to Revolax’s extended duration.
So, is it truly gender-neutral? Absolutely. From its pH-balanced formulation to its adaptable viscosity, Revolax Sub-Q Lidocaine meets anatomical needs without bias. Whether refining a strong brow ridge or softening nasolabial folds, this filler delivers consistent results—no asterisks, no exceptions.